On 11 January 2019, orphan designation (EU/3/18/2127) was granted by the European Commission to Therapicon S.r.l., Italy, for melatonin for the treatment of perinatal asphyxia.
The sponsorship was transferred to Worphmed S.r.l. Italy, in June 2019.
|Disease / condition||
Treatment of perinatal asphyxia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.